Abby Hardy, Author at BioTuesdays

Markets

Canaccord ups Vapotherm PT to $27 from $22

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $27 from $22 after the company’s fourth quarter results beat expectations. The stock closed at $19.85 on March 12. The company, which develops non...

March 13, 2019

Markets

SVB Leerink assumes coverage of CymaBay Therapeutics at OP; PT $22

SVB Leerink analyst Dr. Pasha Sarraf assumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a 12-month price target of $22. The stock closed at $12.36 on March 8. Dr. Sarraf writes that...

March 11, 2019

Developments

Seres Therapeutics in microbiome immuno-oncology collaboration with AstraZeneca

Seres Therapeutics (NASDAQ:MCRB) entered a three-year research collaboration with AstraZeneca to focus on advancing the understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including...

March 11, 2019

Developments

Stellar Biotech, Edesa Biotech to merge in stock swap

Stellar Biotechnologies (NASDAQ:SBOT) has executed a share exchange agreement with closely-held Edesa Biotech to create a new company focused on the development of innovative therapeutics for dermatological and...

March 8, 2019

Developments

“London patient” is second to experience sustained HIV remission following stem cell transplant

A UK man who received a stem cell transplant from a donor with the rare CCR5-delta 32 mutation is believed to effectively be cured from HIV. The CCR5-delta 32 genetic mutation hampers HIV’s ability to enter host cells...

March 6, 2019

Markets

Canaccord recommends buying T2 Biosystems on weakness

Canaccord Genuity reiterated its “buy” rating and $10 price target for T2 Biosystems (NASDAQ:TTOO), saying, “We would buy on weakness.” The stock was quoted at $3.71, down 58 cents, or 13%, in afternoon trading on March...

March 5, 2019

Developments

Titan Pharmaceuticals implant for opioid use disorder attracts media attention in Canada

An implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) for the treatment of opioid use disorder (OUD) is drawing attention in Canada. Marketed under the brand name Probuphine, the first-of-its-kind implant delivers...

March 4, 2019

Markets

SVB Leerink starts MannKind at OP; PT $3

SVB Leerink initiated coverage of MannKind (NASDAQ:MNKD) with an “outperform” rating and a 12-month price target of $3. The stock closed at $1.77 on March 1. Analyst Dr. Pasha Sarraf writes that his rating is based on...

March 4, 2019

Developments

Genetic meta-analysis identifies four new genetic variants associated with Alzheimer’s disease

A genome-wide association study of 94,000 individuals has identified four new genetic variants that play a role in the development of late-onset Alzheimer’s disease (AD). Conducted by an international consortium of...

March 1, 2019

Developments

Novavax Phase 3 ResVax trial misses primary endpoint

Novavax (NASDAQ:NVAX) reported that its Phase 3 PREPARE studyfor ResVax, a RSV (respiratory syncytial virus) F vaccine, did not meet its primary objective of preventing medically significant RSV lower respiratory tract...

March 1, 2019

Author - Abby Hardy

Canaccord ups Vapotherm PT to $27 from $22

SVB Leerink assumes coverage of CymaBay Therapeutics at OP; PT $22

Seres Therapeutics in microbiome immuno-oncology collaboration with AstraZeneca

Stellar Biotech, Edesa Biotech to merge in stock swap

“London patient” is second to experience sustained HIV remission following stem cell transplant

Canaccord recommends buying T2 Biosystems on weakness

Titan Pharmaceuticals implant for opioid use disorder attracts media attention in Canada

SVB Leerink starts MannKind at OP; PT $3

Genetic meta-analysis identifies four new genetic variants associated with Alzheimer’s disease

Novavax Phase 3 ResVax trial misses primary endpoint

Subscribe